Cellectis Introduces Groundbreaking SMART DUAL CAR T-cell Therapy
Cellectis (Euronext Growth: ALCLS - NASDAQ: CLLS), a biotechnology company currently in the clinical stage, has released an article showcasing a revolutionary approach in cell and gene therapies. This publication outlines the company’s SMART DUAL CAR T-cell strategy, which employs TALEN® gene editing technology to tackle the persistent challenges in treating stubborn solid tumors. The unique design of these CAR T-cells targets resistant tumor types while significantly reducing safety concerns.
Challenges in Treating Solid Tumors
Adoptive cell therapy, especially CAR T-cell therapy, has been a beacon of hope for many cancer patients. However, its application has mostly been restricted to certain types of malignancies, with solid tumors proving particularly challenging. Various factors complicate the effective targeting of these tumors, particularly the influence of cancer-associated fibroblasts (CAFs).
CAFs are crucial in forming a tumor microenvironment (TME) that limits T cell infiltration and encourages T cell dysfunction. The lack of tumor-specific antigens (TSAs), along with tumor-associated antigens (TAAs) being present on normal tissues, often results in on-target off-tumor cytotoxicity. This situation raises significant safety concerns that can hinder the effective use of traditional CAR T-cell therapies.
Revolutionary CAR T-cell Engineering Approach
Cellectis' SMART DUAL CAR T-cell technology aims to address these challenges. By utilizing TALEN® gene editing technology, the company has developed allogeneic SMART CAR T-cells with dual targeting capabilities. These T-cells feature a constitutive CAR that specifically targets FAP+ CAFs found in solid tumors, as well as an inducible CAR that activates only when FAP+ CAFs are present, targeting the tumor-associated antigen mesothelin.
This dual-targeting strategy has shown encouraging results. In preclinical models, SMART Dual CAR T-cells exhibited an impressive ability to infiltrate and effectively target triple-negative breast tumors, with no observable instances of on-target off-tumor toxicity. These results suggest a significant advancement in the search for effective treatments for solid tumors.
Future Implications for Cancer Therapies
Dr. Shipra Das, Associate Director of Immuno-Oncology and Innovation Program Management at Cellectis, commented on the potential of this innovative strategy. "This approach could effectively tackle several critical challenges associated with CAR T-cell therapy for solid tumors, such as low CAR T-cell infiltration, immunosuppressive microenvironments, antigen heterogeneity, and safety concerns regarding on-target off-tumor cytotoxicity. It holds great promise for the successful development of CAR T-cells targeted at solid tumors," she stated.
About Cellectis
Cellectis is a pioneering clinical-stage biotechnology company committed to developing transformative cell and gene therapies. By leveraging their advanced gene-editing platform, Cellectis aims to create off-the-shelf, allogeneic CAR T-cell therapies for various cancers. The company is at the forefront of therapeutic gene editing in hematopoietic stem cells, demonstrating its dedication to addressing unmet medical needs with innovative solutions.
With a solid foundation of 25 years of expertise in gene editing, Cellectis continues to utilize its TALEN® technology and the PulseAgile electroporation system. This commitment to harnessing the immune system's potential reflects the company’s goal of revolutionizing cancer treatment and enhancing patient outcomes. Cellectis is headquartered in Paris, France, with additional offices in New York and Raleigh.
Frequently Asked Questions
What is the SMART DUAL CAR T-cell approach?
The SMART DUAL CAR T-cell approach involves engineering CAR T-cells to specifically target cancer-associated fibroblasts while also enabling the targeting of tumor-associated antigens in a selective manner, thereby minimizing potential safety risks.
Why are solid tumors difficult to treat with CAR T-cell therapy?
Solid tumors are challenging to treat due to the immunosuppressive tumor microenvironment, low levels of tumor-specific antigens, and the presence of tumor-associated antigens on normal tissues, which can lead to off-target effects.
What technology does Cellectis use for gene editing?
Cellectis utilizes TALEN® gene editing technology to engineer its CAR T-cells, allowing for the creation of precise and effective therapeutic candidates aimed at solid tumors.
How does the inducible CAR function in the SMART Dual CAR T-cell?
The inducible CAR activates only in the presence of specific markers on CAFs, enabling targeted therapy that minimizes the risk of harming surrounding healthy tissues.
What are Cellectis' main objectives in gene therapy?
Cellectis aims to develop effective and innovative cell and gene therapies that enhance patient outcomes by addressing unmet medical needs and improving cancer treatment options.
